Beam Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade Beam Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BEAM
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201.
CEOJohn Evans
CEOJohn Evans
Employees483
Employees483
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded2017
Founded2017
Employees483
Employees483
BEAM Key Statistics
Market cap2.80B
Market cap2.80B
Price-Earnings ratio-6.52
Price-Earnings ratio-6.52
Dividend yield—
Dividend yield—
Average volume1.23M
Average volume1.23M
High today$29.05
High today$29.05
Low today$27.59
Low today$27.59
Open price$28.52
Open price$28.52
Volume461.82K
Volume461.82K
52 Week high$35.25
52 Week high$35.25
52 Week low$13.53
52 Week low$13.53
Stock Snapshot
With a market cap of 2.8B, Beam Therapeutics(BEAM) trades at $27.60. The stock has a price-to-earnings ratio of -6.52.
During the trading session on 2026-01-08, Beam Therapeutics(BEAM) shares reached a daily high of $29.05 and a low of $27.59. At a current price of $27.60, the stock is +0.0% higher than the low and still -5.0% under the high.
Trading activity shows a volume of 461.82K, compared to an average daily volume of 1.23M.
The stock's 52-week range extends from a low of $13.53 to a high of $35.25.
The stock's 52-week range extends from a low of $13.53 to a high of $35.25.
Analyst ratings
83%
of 18 ratingsBuy
83.3%
Hold
16.7%
Sell
0%
People also own
Based on the portfolios of people who own BEAM. This list is generated using Robinhood data, and it’s not a recommendation.